Small Molecules
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
366
NCT05429632
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Phase: Phase 3
Role: Lead Sponsor
Start: Jun 16, 2022
Completion: Nov 30, 2029
Loading map...